Viracta Therapeutics Investor Relations Material
Latest events
Study Update
Viracta Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Viracta Therapeutics Inc
Access all reports
Viracta Therapeutics Inc. is a precision oncology company focused on developing treatments for virus-associated cancers. The company's leading product candidate, Nana-val, is an all-oral combination therapy comprising its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Beyond Nana-val, Viracta is exploring the "Kick and Kill" approach for other virus-related cancers, aiming to leverage its expertise in oncology to address the needs of patients with virus-associated malignancies globally. Headquartered in Cardiff-by-the-Sea, California, Viracta Therapeutics Inc.'s shares are listed on the Nasdaq.
Key slides for Viracta Therapeutics Inc
Study Update
Viracta Therapeutics Inc
Study Update
Viracta Therapeutics Inc
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
VIRX
Country
🇺🇸 United States